NCT04158752View on ClinicalTrials.gov

Anti-CGRP for Inflamation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia

PHASE4CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

July 24, 2020

Primary Completion Date

January 4, 2023

Study Completion Date

January 4, 2023

Conditions

Trigeminal NeuralgiaGlossopharyngeal Neuralgia

Interventions

DRUG

Galcanezumab

Injection of study drug at 3 timepoints (day 30, day 60, day 90)

Trial Locations (1)

27705

Duke University, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

lead

Duke University

OTHER